
**UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN THE
PEOPLE'S REPUBLIC OF CHINA –
RECOGNITION AND ENFORCEMENT PROCEEDINGS IN SHANGHAI**

The Board of Directors ("**Board**") of OUE Lippo Healthcare Limited ("**Company**") refers to the Company's announcement on 30 December 2019 ("**Announcement**") in relation to its application to recognize and enforce the Final Arbitration Award for the sum of RMB 58,837,898.20, USD 32,840,185.87 and SGD 842,822.66 to the Company, as well as interest, obtained against David Lin in arbitration proceedings before the Singapore International Arbitration Centre (the "**Arbitration Award**") in the People's Republic of China ("**PRC**") (collectively, the "**Shanghai Recognition and Enforcement Proceedings**"). Unless otherwise defined, all capitalised terms and references used herein shall bear the same meanings ascribed to them in the Announcement.

The Board wishes to update the shareholders that the Company has successfully obtained an order from the Shanghai No. 1 Intermediate Court to recognise and enforce the Arbitration Award in the PRC. In particular:

- (a) As announced on 30 December 2019, the Company applied on 30 January 2019 to the Shanghai No. 1 Intermediate Court for the Arbitration Award against David Lin to be recognised and enforceable under PRC laws. A hearing was held on 24 April 2019 for parties to exchange their evidence.
- (b) Separately, on 6 December 2019, the Company obtained an order from the Shanghai No. 1 Intermediate Court to freeze up to RMB 20 million of David Lin's assets in PRC, pending the Shanghai Recognition and Enforcement Proceedings.
- (c) On 21 April 2020, the Company was informed by its PRC counsel that the Shanghai No. 1 Intermediate Court has granted an order on 20 April 2020 recognising the Arbitration Award, with the effect that the Arbitration Award is now enforceable against David Lin in the PRC.
- (d) The order from the Shanghai No. 1 Intermediate Court to freeze up to RMB 20 million of David Lin's assets in the PRC remains in force, and the Company will be working with its PRC counsel to enforce the Arbitration Award against David Lin's assets in the PRC.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
22 April 2020

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).